Aevi Genomic Medicine, Inc. announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial. The ASCEND trial is a genomically-guided study in pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder (ADHD) assessing the safety and efficacy of AEVI-001, a novel, non-stimulant therapy. Part B of the ASCEND trial is studying pediatric and adolescent patients with ADHD without mGluR mutations, Part A of the ASCEND trial is studying a mGluR mutation positive genetic subset of pediatric and adolescent patients. Part A completed enrollment in August 2018, the accelerated enrollment in Part B will allow the Company to provide complete top line data for both Parts A and B of the ASCEND trial in January 2019, individual and pooled analysis of Parts A and B will be conducted simultaneously, and will inform the design of the planned Phase 3 program. Development of AEVI-004, a new chemical entity (NCE), co-crystal of AEVI-001 continues in order to maximize the value of Part B of the ASCEND trial. AEVI-004 potentially expands the composition of matter patent protection through 2039 and broadens market potential beyond ADHD into other neuropsychiatric diseases.